INTERIM REPORT OCTOBER 1st 2022 – DECEMBER 31st 2022
SELECTIMMUNE PHARMA IN BRIEF SelectImmune Pharma is an innovative biotech company that develops novel immunotherapies against infection. • Excessive innate immune responses to infection cause symptoms and pathology in acute pyelone phritis and acute cystitis. Immunomodulation is therefore a realistic option for treating these condi tions as alternatives or complements to antibiotics. • Several of the company’s drug candidates have shown protective effects against bacterial infection in animal models, including acute cystitis, severe kidney infection and urosepsis. • One drug